Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
Hydrochlorothiazide was granted FDA approval on 12 February 1959.
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
- Associated Therapies
- -
3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 583
- Registration Number
- NCT00153049
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Taya-gun, Gunma, Japan
Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome
- Conditions
- Metabolic SyndromeHypertension
- Interventions
- First Posted Date
- 2005-05-10
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT00110422
- Locations
- 🇪🇸
Local Institution, Zaragoza, Spain
Genetic Epidemiology of Responses to Antihypertensives
- Conditions
- HypertensionCardiovascular DiseasesHeart Diseases
- Interventions
- First Posted Date
- 2000-05-26
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 1200
- Registration Number
- NCT00005520
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Diuretics, Hypertension, and Arrhythmias Clinical Trial
- Conditions
- Cardiovascular DiseasesDeath, Sudden, CardiacHeart ArrestHeart DiseasesHypertension
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 233
- Registration Number
- NCT00000525
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.